Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Ph 1a, First-in-Man, Single Ascending Dose & Multiple Ascending Dose Safety, Tolerability and PK Study of a Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) in Healthy Adult Subjects
NCT04233814 is registered in ClinicalTrials.gov with Rein Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-Controlled, Ph 1a, First-in-Man, Single Ascending Dose & Multiple Ascending Dose Safety, Tolerability and PK Study of a Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) in Healthy Adult Subjects
- Lead sponsor
- Rein Therapeutics
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- January 20, 2020
- Completion date
- December 23, 2021
- Enrollment
- 71 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.